Q04206 (TF65_HUMAN) Reviewed, UniProtKB/Swiss-Prot
Last modified
May 1, 2013.
Version 162.
History...
Names·Attributes·General annotation·Ontologies·Interactions·Alt products·Sequence annotation·Sequences·References·Web links·Cross-refs·Entry info·DocumentsCustomize order
Names·Attributes·General annotation·Ontologies·Interactions·Alt products·Sequence annotation·Sequences·References·Web links·Cross-refs·Entry info·DocumentsCustomize orderNames and origin
| Protein names | Recommended name: Transcription factor p65 Alternative name(s): Nuclear factor NF-kappa-B p65 subunit Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 | ||||
| Gene names |
| ||||
| Organism | Homo sapiens (Human) [Reference proteome] | ||||
| Taxonomic identifier | 9606 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo![]() |
Protein attributes
| Sequence length | 551 AA. |
| Sequence status | Complete. |
| Protein existence | Evidence at protein level |
General annotation (Comments)
| Function | NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. Ref.15 Ref.25 Ref.42 Ref.46 Ref.49 Ref.53 |
| Subunit structure | Component of the NF-kappa-B p65-p50 complex. Component of the NF-kappa-B p65-c-Rel complex. Homodimer; component of the NF-kappa-B p65-p65 complex. Component of the NF-kappa-B p65-p52 complex. May interact with ETHE1. Binds AES and TLE1. Interacts with TP53BP2. Binds to and is phosphorylated by the activated form of either RPS6KA4 or RPS6KA5. Interacts with ING4 and this interaction may be indirect. Interacts with CARM1, USP48 and UNC5CL. Interacts with IRAK1BP1 By similarity. Interacts with NFKBID By similarity. Interacts with NFKBIA. Interacts with GSK3B. Interacts with NFKBIB By similarity. Interacts with NFKBIE. Interacts with NFKBIZ. Interacts with EHMT1 (via ANK repeats) By similarity. Part of a 70-90 kDa complex at least consisting of CHUK, IKBKB, NFKBIA, RELA, IKBKAP and MAP3K14. Interacts with HDAC3; HDAC3 mediates the deacetylation of RELA. Interacts with HDAC1; the interaction requires non-phosphorylated RELA. Interacts with CBP; the interaction requires phosphorylated RELA. Interacts (phosphorylated at 'Thr-254') with PIN1; the interaction inhibits p65 binding to NFKBIA. Interacts with SOCS1. Interacts with UXT. Interacts with MTDH and PHF11. Interacts with ARRB2. Interacts with human respiratory syncytial virus (HRSV) protein M2-1. Interacts with NFKBIA (when phosphorylated), the interaction is direct; phosphorylated NFKBIA is part of a SCF(BTRC)-like complex lacking CUL1. Interacts with RNF25. Interacts (via C-terminus) with DDX1. Interacts with UFL1 and COMMD1. Interacts with BRMS1; this promotes deacetylation of 'Lys-310'. Interacts with NOTCH2 By similarity. Directly interacts with MEN1; this interaction represses NFKB-mediated transactivation. Interacts with AKIP1, which promotes the phosphorylation and nuclear retention of RELA. Interacts (via the RHD) with GFI1; the interaction, after bacterial lipopolysaccharide (LPS) stimulation, inhibits the transcriptional activity by interfering with the DNA-binding activity to target gene promoter DNA. Ref.7 Ref.8 Ref.9 Ref.10 Ref.11 Ref.12 Ref.14 Ref.15 Ref.16 Ref.18 Ref.19 Ref.20 Ref.22 Ref.23 Ref.25 Ref.26 Ref.27 Ref.28 Ref.31 Ref.32 Ref.36 Ref.38 Ref.39 Ref.40 Ref.42 Ref.43 Ref.44 Ref.46 Ref.47 Ref.48 Ref.49 Ref.51 Ref.53 |
| Subcellular location | Nucleus. Cytoplasm. Note: Colocalized with DDX1 in the nucleus upon TNF-alpha induction By similarity. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 in the nucleus after LPS stimulation. Ref.25 Ref.36 Ref.49 Ref.53 |
| Domain | the 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors. Ref.6 Ref.45 |
| Post-translational modification | Ubiquitinated, leading to its proteasomal degradation. Degradation is required for termination of NF-kappa-B response. Ref.30 Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes the formation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity. Phosphorylation at Ser-311 disrupts the interaction with EHMT1 without preventing monomethylation at Lys-310 and relieves the repression of target genes By similarity. Phosphorylation at Ser-311 disrupts the interaction with EHMT1 and promotes transcription factor activity By similarity. Phosphorylation on Ser-536 stimulates acetylation on Lys-310 and interaction with CBP; the phosphorylated and acetylated forms show enhanced transcriptional activity. Phosphorylation at Ser-276 by RPS6KA4 and RPS6KA5 promotes its transactivation and transcriptional activities. Ref.13 Ref.17 Ref.22 Ref.23 Ref.27 Ref.29 Ref.33 Ref.34 Ref.35 Ref.41 Reversibly acetylated; the acetylation seems to be mediated by CBP, the deacetylation by HDAC3 and SIRT2. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA. Acetylation at Lys-310 is required for full transcriptional activity in the absence of effects on DNA binding and NFKBIA association. Acetylation can also lower DNA-binding and results in nuclear export. Interaction with BRMS1 promotes deacetylation of Lys-310. Lys-310 is deacetylated by SIRT2. S-nitrosylation of Cys-38 inactivates the enzyme activity By similarity. Sulfhydration at Cys-38 mediates the anti-apoptotic activity by promoting the interaction with RPS3 and activating the transcription factor activity By similarity. Sumoylation by PIAS3 negatively regulates DNA-bound activated NF-kappa-B. Ref.55 |
| Sequence similarities | Contains 1 RHD (Rel-like) domain. |
Ontologies
Binary interactions
With | Entry | #Exp. | IntAct | Notes |
|---|---|---|---|---|
| itself | 3 | EBI-73886,EBI-73886 | ||
| AATF | Q9NY61 | 3 | EBI-73886,EBI-372428 | |
| ATF3 | P18847 | 4 | EBI-73886,EBI-712767 | |
| CDK5RAP3 | Q96JB5 | 4 | EBI-73886,EBI-718818 | |
| CHUK | O15111 | 2 | EBI-73886,EBI-81249 | |
| COMMD1 | Q8N668 | 7 | EBI-73886,EBI-1550112 | |
| CREBBP | Q92793 | 3 | EBI-73886,EBI-81215 | |
| DHX9 | Q08211 | 4 | EBI-73886,EBI-352022 | |
| EHMT1 | Q9H9B1 | 3 | EBI-73886,EBI-766087 | |
| ESR1 | P03372 | 7 | EBI-73886,EBI-78473 | |
| GFI1 | Q99684 | 2 | EBI-73886,EBI-949368 | |
| HDAC1 | Q13547 | 5 | EBI-73886,EBI-301834 | |
| KEAP1 | Q14145 | 4 | EBI-73886,EBI-751001 | |
| LMO2 | P25791 | 3 | EBI-73886,EBI-739696 | |
| MAPK10 | P53779 | 2 | EBI-73886,EBI-713543 | |
| NFKB1 | P19838 | 7 | EBI-73886,EBI-300010 | |
| NFKBIA | P25963 | 12 | EBI-73886,EBI-307386 | |
| NFKBIB | Q15653 | 6 | EBI-73886,EBI-352889 | |
| P/V | P0C774 | 3 | EBI-73886,EBI-3650423 | From a different organism. |
| RPS3 | P23396 | 6 | EBI-73886,EBI-351193 | |
| SIRT1 | Q96EB6 | 4 | EBI-73886,EBI-1802965 | |
| SIRT6 | Q8N6T7 | 4 | EBI-73886,EBI-712415 | |
| STAT3 | P40763 | 4 | EBI-73886,EBI-518675 | |
| TGM2 | P21980 | 3 | EBI-73886,EBI-727668 | |
| TP53BP2 | Q13625-2 | 6 | EBI-73886,EBI-287091 | |
| UXT | Q9UBK9 | 5 | EBI-73886,EBI-357355 |
Alternative products
| This entry describes 4 isoforms produced by alternative splicing. [Align] [Select] | ||||||
| Isoform 1 (identifier: Q04206-1) Also known as: p65; This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | ||||||
| Isoform 2 (identifier: Q04206-2) Also known as: p65 delta 2; The sequence of this isoform differs from the canonical sequence as follows: 13-25: Missing. 506-506: Missing. | ||||||
| Isoform 3 (identifier: Q04206-3) Also known as: p65 delta; The sequence of this isoform differs from the canonical sequence as follows: 222-231: Missing. | ||||||
| Isoform 4 (identifier: Q04206-4) The sequence of this isoform differs from the canonical sequence as follows: 143-145: Missing. | ||||||
| Note: No experimental confirmation available. |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecule processing | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 551 | 551 | Transcription factor p65 | PRO_0000205169 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Regions | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Domain | 19 – 306 | 288 | RHD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Region | 415 – 459 | 45 | Activation domain | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Motif | 301 – 304 | 4 | Nuclear localization signal Potential | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Motif | 536 – 544 | 9 | 9aaTAD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amino acid modifications | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 38 | 1 | Cysteine persulfide; alternate By similarity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 38 | 1 | S-nitrosocysteine; alternate By similarity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 122 | 1 | N6-acetyllysine; by PCAF and EP300; alternate Ref.24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 123 | 1 | N6-acetyllysine; by PCAF and EP300; alternate Ref.24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 254 | 1 | Phosphothreonine Ref.27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 276 | 1 | Phosphoserine; by RPS6KA4 and RPS6KA5 Ref.23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 281 | 1 | Phosphoserine Probable | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 310 | 1 | N6-acetyllysine; alternate Ref.21 Ref.37 Ref.42 Ref.50 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 310 | 1 | N6-methyllysine; by SETD6 By similarity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 311 | 1 | Phosphoserine; by PKC/PRKCZ By similarity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 435 | 1 | Phosphothreonine Ref.29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 468 | 1 | Phosphoserine; by IKKB and IKKE Ref.34 Ref.41 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 505 | 1 | Phosphothreonine; by CHEK1 Ref.33 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 529 | 1 | Phosphoserine; by CK2 Ref.17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 536 | 1 | Phosphoserine; by IKKB Ref.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cross-link | 37 | Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO3) Ref.55 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cross-link | 122 | Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO3); alternate Ref.55 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cross-link | 123 | Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO3); alternate Ref.55 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Natural variations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 13 – 25 | 13 | Missing in isoform 2. | VSP_005587 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 143 – 145 | 3 | Missing in isoform 4. | VSP_031245 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 222 – 231 | 10 | Missing in isoform 3. | VSP_012031 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 506 | 1 | Missing in isoform 2. | VSP_005588 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Experimental info | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 254 | 1 | T → A: Abolishes interaction with PIN1. Ref.27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 276 | 1 | S → C: Loss of phosphorylation. Ref.23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 49 | 1 | E → R in CAA80524. Ref.2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 180 | 1 | S → P in AAA36408. Ref.1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 372 – 380 | 9 | QISQASALA → RSARPRLG in CAA80524. Ref.2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Secondary structure | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Helix Strand Turn | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 21 – 25 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 30 – 32 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 39 – 41 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 53 – 55 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 60 – 63 | 4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 68 – 80 | 13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 87 – 92 | 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 97 – 104 | 8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 109 – 112 | 4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 117 – 119 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 123 – 125 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 126 – 129 | 4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Turn | 130 – 137 | 8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Turn | 145 – 148 | 4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 156 – 166 | 11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 168 – 173 | 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 183 – 188 | 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 196 – 200 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 202 – 205 | 4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 211 – 217 | 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 225 – 230 | 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 233 – 238 | 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 241 – 243 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Turn | 246 – 248 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 249 – 253 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 258 – 260 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 266 – 273 | 8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Turn | 275 – 277 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 284 – 289 | 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 294 – 302 | 9 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 306 – 312 | 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sequences
| ||||||||||||||||||||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kappa B." Ruben S.M., Dillon P.J., Schreck R., Henkel T., Chen C.-H., Maher M., Baeuerle P.A., Rosen C.A. Science 251:1490-1493(1991) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). |
| [2] | "Genomic organization of the gene encoding the p65 subunit of NF-kappa B: multiple variants of the p65 protein may be generated by alternative splicing." Deloukas P., van Loon A.P.G.M. Hum. Mol. Genet. 2:1895-1900(1993) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING. |
| [3] | "An alternatively spliced transcript, p65 delta 2, of the gene encoding the p65 subunit of the transcription factor NF-kappa B." Lyle R., Valleley E.M., Sharpe P.T., Hewitt J.E. Gene 138:265-266(1994) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). Tissue: Bone. |
| [4] | "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4). Tissue: Colon. |
| [5] | SeattleSNPs variation discovery resource Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 4-551. |
| [6] | "Functional characterization of the NF-kappa B p65 transcriptional activator and an alternatively spliced derivative." Ruben S.M., Narayanan R., Klement J.F., Chen C.-H., Rosen C.A. Mol. Cell. Biol. 12:444-454(1992) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 214-239 (ISOFORMS 1/2 AND 3), ACTIVATION DOMAIN. |
| [7] | "A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene." Hansen S.K., Nerlov C., Zabel U., Verde P., Johnsen M., Baeuerle P.A., Blasi F. EMBO J. 11:205-213(1992) [PubMed] [Europe PMC] [Abstract] Cited for: IDENTIFICATION IN THE NF-KAPPA-B P65-P50 COMPLEX, IDENTIFICATION IN THE NF-KAPPA-B P65-C-REL COMPLEX. |
| [8] | "I kappa B/MAD-3 masks the nuclear localization signal of NF-kappa B p65 and requires the transactivation domain to inhibit NF-kappa B p65 DNA binding." Ganchi P.A., Sun S.C., Greene W.C., Ballard D.W. Mol. Biol. Cell 3:1339-1352(1992) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH NFKBIA. |
| [9] | "Activation of multiple NF-kappa B/Rel DNA-binding complexes by tumor necrosis factor." Beg A.A., Baldwin A.S. Jr. Oncogene 9:1487-1492(1994) [PubMed] [Europe PMC] [Abstract] Cited for: IDENTIFICATION IN THE NF-KAPPA-B P65-C-REL COMPLEX, IDENTIFICATION IN THE NF-KAPPA-B P65-P52 COMPLEX. |
| [10] | "Regulation of intercellular adhesion molecule-1 gene by tumor necrosis factor-alpha is mediated by the nuclear factor-kappaB heterodimers p65/p65 and p65/c-Rel in the absence of p50." Aoudjit F., Brochu N., Belanger B., Stratowa C., Hiscott J., Audette M. Cell Growth Differ. 8:335-342(1997) [PubMed] [Europe PMC] [Abstract] Cited for: IDENTIFICATION IN THE NF-KAPPA-B P65-P65 COMPLEX, IDENTIFICATION IN THE NF-KAPPA-B P65-C-REL COMPLEX. |
| [11] | "A new member of the IkappaB protein family, IkappaB epsilon, inhibits RelA (p65)-mediated NF-kappaB transcription." Li Z., Nabel G.J. Mol. Cell. Biol. 17:6184-6190(1997) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH NFKBIE. |
| [12] | "IKAP is a scaffold protein of the IkappaB kinase complex." Cohen L., Henzel W.J., Baeuerle P.A. Nature 395:292-296(1998) [PubMed] [Europe PMC] [Abstract] Cited for: IDENTIFICATION IN A COMPLEX WITH CHUK; IKBKB; NFKBIA; IKBKAP AND MAP3K14. |
| [13] | "IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain." Sakurai H., Chiba H., Miyoshi H., Sugita T., Toriumi W. J. Biol. Chem. 274:30353-30356(1999) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION AT SER-536. |
| [14] | "NF-kappaB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2." Yang J.-P., Hori M., Takahashi N., Kawabe T., Kato H., Okamoto T. Oncogene 18:5177-5186(1999) [PubMed] [Europe PMC] [Abstract] Cited for: TISSUE SPECIFICITY, INTERACTION WITH TP53BP2. |
| [15] | "Yersinia enterocolitica invasin protein triggers IL-8 production in epithelial cells via activation of Rel p65-p65 homodimers." Schulte R., Grassl G.A., Preger S., Fessele S., Jacobi C.A., Schaller M., Nelson P.J., Autenrieth I.B. FASEB J. 14:1471-1484(2000) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION, IDENTIFICATION IN THE NF-KAPPA-B P65-P65 COMPLEX. |
| [16] | "Inhibition of nuclear factor-kappaB-mediated transcription by association with the amino-terminal enhancer of split, a Groucho-related protein lacking WD40 repeats." Tetsuka T., Uranishi H., Imai H., Ono T., Sonta S., Takahashi N., Asamitsu K., Okamoto T. J. Biol. Chem. 275:4383-4390(2000) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH AES AND TLE1. |
| [17] | "Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II." Wang D., Westerheide S.D., Hanson J.L., Baldwin A.S. Jr. J. Biol. Chem. 275:32592-32597(2000) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION AT SER-529. |
| [18] | "The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation." Heppner C., Bilimoria K.Y., Agarwal S.K., Kester M., Whitty L.J., Guru S.C., Chandrasekharappa S.C., Collins F.S., Spiegel A.M., Marx S.J., Burns A.L. Oncogene 20:4917-4925(2001) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH MEN1. |
| [19] | "Duration of nuclear NF-kappaB action regulated by reversible acetylation." Chen L.F., Fischle W., Verdin E., Greene W.C. Science 293:1653-1657(2001) [PubMed] [Europe PMC] [Abstract] Cited for: ACETYLATION, INTERACTION WITH HDAC3. |
| [20] | "A novel protein overexpressed in hepatoma accelerates export of NF-kappa B from the nucleus and inhibits p53-dependent apoptosis." Higashitsuji H., Higashitsuji H., Nagao T., Nonoguchi K., Fujii S., Itoh K., Fujita J. Cancer Cell 2:335-346(2002) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH ETHE1. |
| [21] | "Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB." Chen L.F., Mu Y., Greene W.C. EMBO J. 21:6539-6548(2002) [PubMed] [Europe PMC] [Abstract] Cited for: ACETYLATION AT LYS-218; LYS-221 AND LYS-310. |
| [22] | "The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1." Zhong H., May M.J., Jimi E., Ghosh S. Mol. Cell 9:625-636(2002) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH CBP AND HDAC1, PHOSPHORYLATION. |
| [23] | "Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1)." Vermeulen L., De Wilde G., Van Damme P., Vanden Berghe W., Haegeman G. EMBO J. 22:1313-1324(2003) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH RPS6KA5, MUTAGENESIS OF SER-276, PHOSPHORYLATION AT SER-276. |
| [24] | "Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65." Kiernan R., Bres V., Ng R.W., Coudart M.-P., El Messaoudi S., Sardet C., Jin D.-Y., Emiliani S., Benkirane M. J. Biol. Chem. 278:2758-2766(2003) [PubMed] [Europe PMC] [Abstract] Cited for: ACETYLATION AT LYS-122 AND LYS-123. |
| [25] | "RING finger protein AO7 supports NF-kappaB-mediated transcription by interacting with the transactivation domain of the p65 subunit." Asamitsu K., Tetsuka T., Kanazawa S., Okamoto T. J. Biol. Chem. 278:26879-26887(2003) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH RNF25. |
| [26] | "Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability." Demarchi F., Bertoli C., Sandy P., Schneider C. J. Biol. Chem. 278:39583-39590(2003) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH GSK3B. |
| [27] | "Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA." Ryo A., Suizu F., Yoshida Y., Perrem K., Liou Y.C., Wulf G., Rottapel R., Yamaoka S., Lu K.P. Mol. Cell 12:1413-1426(2003) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION AT THR-254, INTERACTION WITH PIN1 AND SOCS1, MUTAGENESIS OF THR-254. |
| [28] | "Identification of a ZU5 and death domain-containing inhibitor of NF-kappaB." Zhang J., Xu L.-G., Han K.-J., Shu H.-B. J. Biol. Chem. 279:17819-17825(2004) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH UNC5CL. |
| [29] | "Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF-kappaB activation by protein phosphatase 4-mediated NF-kappaB p65 Thr dephosphorylation." Yeh P.Y., Yeh K.H., Chuang S.E., Song Y.C., Cheng A.L. J. Biol. Chem. 279:26143-26148(2004) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION AT THR-435. |
| [30] | "Degradation of promoter-bound p65/RelA is essential for the prompt termination of the nuclear factor kappaB response." Saccani S., Marazzi I., Beg A.A., Natoli G. J. Exp. Med. 200:107-113(2004) [PubMed] [Europe PMC] [Abstract] Cited for: UBIQUITINATION. |
| [31] | "Identification of beta-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-kappaB pathways." Gao H., Sun Y., Wu Y., Luan B., Wang Y., Qu B., Pei G. Mol. Cell 14:303-317(2004) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH ARRB2. |
| [32] | "The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis." Garkavtsev I., Kozin S.V., Chernova O., Xu L., Winkler F., Brown E., Barnett G.H., Jain R.K. Nature 428:328-332(2004) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH ING4. |
| [33] | "Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor." Rocha S., Garrett M.D., Campbell K.J., Schumm K., Perkins N.D. EMBO J. 24:1157-1169(2005) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION AT THR-505. |
| [34] | "IKKbeta phosphorylates p65 at S468 in transactivation domain 2." Schwabe R.F., Sakurai H. FASEB J. 19:1758-1760(2005) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION AT SER-468. |
| [35] | "cis-acting, element-specific transcriptional activity of differentially phosphorylated nuclear factor-kappa B." Anrather J., Racchumi G., Iadecola C. J. Biol. Chem. 280:244-252(2005) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION AT SER-281. |
| [36] | "COMMD proteins, a novel family of structural and functional homologs of MURR1." Burstein E., Hoberg J.E., Wilkinson A.S., Rumble J.M., Csomos R.A., Komarck C.M., Maine G.N., Wilkinson J.C., Mayo M.W., Duckett C.S. J. Biol. Chem. 280:22222-22232(2005) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH COMMD1, SUBCELLULAR LOCATION. |
| [37] | "NF-kappaB RelA phosphorylation regulates RelA acetylation." Chen L.F., Williams S.A., Mu Y., Nakano H., Duerr J.M., Buckbinder L., Greene W.C. Mol. Cell. Biol. 25:7966-7975(2005) [PubMed] [Europe PMC] [Abstract] Cited for: ACETYLATION AT LYS-310. |
| [38] | "Respiratory syncytial virus M2-1 protein induces the activation of nuclear factor kappa B." Reimers K., Buchholz K., Werchau H. Virology 331:260-268(2005) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH HRSV PROTEIN M2-1. |
| [39] | "Activation of the nuclear factor kappaB pathway by astrocyte elevated gene-1: implications for tumor progression and metastasis." Emdad L., Sarkar D., Su Z.-Z., Randolph A., Boukerche H., Valerie K., Fisher P.B. Cancer Res. 66:1509-1516(2006) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH MTDH. |
| [40] | "Human ubiquitin specific protease 31 is a deubiquitinating enzyme implicated in activation of nuclear factor-kappaB." Tzimas C., Michailidou G., Arsenakis M., Kieff E., Mosialos G., Hatzivassiliou E.G. Cell. Signal. 18:83-92(2006) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH USP48. |
| [41] | "Inducible phosphorylation of NF-kappa B p65 at serine 468 by T cell costimulation is mediated by IKK epsilon." Mattioli I., Geng H., Sebald A., Hodel M., Bucher C., Kracht M., Schmitz M.L. J. Biol. Chem. 281:6175-6183(2006) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION AT SER-468. |
| [42] | "Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis." Liu Y., Smith P.W., Jones D.R. Mol. Cell. Biol. 26:8683-8696(2006) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH BRMS1, FUNCTION, ACETYLATION AT LYS-310. |
| [43] | "Coactivator-associated arginine methyltransferase-1 enhances nuclear factor-kappaB-mediated gene transcription through methylation of histone H3 at arginine 17." Miao F., Li S., Chavez V., Lanting L., Natarajan R. Mol. Endocrinol. 20:1562-1573(2006) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH CARM1. |
| [44] | "IL-1 receptor-associated kinase 1 is critical for latent membrane protein 1-induced p65/RelA serine 536 phosphorylation and NF-kappaB activation." Song Y.J., Jen K.Y., Soni V., Kieff E., Cahir-McFarland E. Proc. Natl. Acad. Sci. U.S.A. 103:2689-2694(2006) [PubMed] [Europe PMC] [Abstract] Cited for: IDENTIFICATION IN THE NF-KAPPA-B P65-P52 COMPLEX. |
| [45] | "Nine-amino-acid transactivation domain: establishment and prediction utilities." Piskacek S., Gregor M., Nemethova M., Grabner M., Kovarik P., Piskacek M. Genomics 89:756-768(2007) [PubMed] [Europe PMC] [Abstract] Cited for: DOMAIN. |
| [46] | "UXT is a novel and essential cofactor in the NF-kappaB transcriptional enhanceosome." Sun S., Tang Y., Lou X., Zhu L., Yang K., Zhang B., Shi H., Wang C. J. Cell Biol. 178:231-244(2007) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION, INTERACTION WITH UXT. |
| [47] | "Functional characterization of the atopy-associated gene PHF11." Clarke E., Rahman N., Page N., Rolph M.S., Stewart G.J., Jones G.J. J. Allergy Clin. Immunol. 121:1148-1154(2008) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH PHF11. |
| [48] | "AKIP1 enhances NF-kappaB-dependent gene expression by promoting the nuclear retention and phosphorylation of p65." Gao N., Asamitsu K., Hibi Y., Ueno T., Okamoto T. J. Biol. Chem. 283:7834-7843(2008) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH AKIP1. |
| [49] | "The DEAD-box RNA helicase DDX1 interacts with RelA and enhances nuclear factor kappaB-mediated transcription." Ishaq M., Ma L., Wu X., Mu Y., Pan J., Hu J., Hu T., Fu Q., Guo D. J. Cell. Biochem. 106:296-305(2009) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION, INTERACTION WITH DDX1, SUBCELLULAR LOCATION. |
| [50] | "Lysine acetylation targets protein complexes and co-regulates major cellular functions." Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., Olsen J.V., Mann M. Science 325:834-840(2009) [PubMed] [Europe PMC] [Abstract] Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-310, MASS SPECTROMETRY. |
| [51] | "A novel LZAP-binding protein, NLBP, inhibits cell invasion." Kwon J., Cho H.J., Han S.H., No J.G., Kwon J.Y., Kim H. J. Biol. Chem. 285:12232-12240(2010) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH UFL1. |
| [52] | "SIRT2 regulates NF-kappaB dependent gene expression through deacetylation of p65 Lys310." Rothgiesser K.M., Erener S., Waibel S., Luscher B., Hottiger M.O. J. Cell Sci. 123:4251-4258(2010) [PubMed] [Europe PMC] [Abstract] Cited for: DEACETYLATION BY SIRT2. |
| [53] | "Zinc finger protein Gfi1 controls the endotoxin-mediated Toll-like receptor inflammatory response by antagonizing NF-kappaB p65." Sharif-Askari E., Vassen L., Kosan C., Khandanpour C., Gaudreau M.C., Heyd F., Okayama T., Jin J., Rojas M.E., Grimes H.L., Zeng H., Moroy T. Mol. Cell. Biol. 30:3929-3942(2010) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH GFI1, SUBCELLULAR LOCATION, INDUCTION, FUNCTION. |
| [54] | "Initial characterization of the human central proteome." Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J. BMC Syst. Biol. 5:17-17(2011) [PubMed] [Europe PMC] [Abstract] Cited for: IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. |
| [55] | "NF-kappaB repression by PIAS3 mediated RelA SUMOylation." Liu Y., Bridges R., Wortham A., Kulesz-Martin M. PLoS ONE 7:E37636-E37636(2012) [PubMed] [Europe PMC] [Abstract] Cited for: SUMOYLATION AT LYS-37; LYS-122 AND LYS-123 BY PIAS3. |
| [56] | "Structure of an IkappaBalpha/NF-kappaB complex." Jacobs M.D., Harrison S.C. Cell 95:749-758(1998) [PubMed] [Europe PMC] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS). |
| + | Additional computationally mapped references. |
Cross-references
Sequence databases | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMBL GenBank DDBJ | M62399 mRNA. Translation: AAA36408.1. Z22948 Z22951 Genomic DNA. Translation: CAA80524.2.L19067 mRNA. Translation: AAA20946.1. BC033522 mRNA. Translation: AAH33522.1. AY455868 Genomic DNA. Translation: AAR13863.1. | ||||||||||||||||||||||||||||||||||||||||||
| IPI | IPI00219084. IPI00386448. IPI00479470. IPI00884950. | ||||||||||||||||||||||||||||||||||||||||||
| PIR | A40851. I53719. A42017. S51782. | ||||||||||||||||||||||||||||||||||||||||||
| RefSeq | NP_001138610.1. NM_001145138.1. NP_001230913.1. NM_001243984.1. NP_068810.3. NM_021975.3. | ||||||||||||||||||||||||||||||||||||||||||
| UniGene | Hs.502875. | ||||||||||||||||||||||||||||||||||||||||||
3D structure databases | |||||||||||||||||||||||||||||||||||||||||||
| PDBe RCSB PDB PDBj |
| ||||||||||||||||||||||||||||||||||||||||||
| DisProt | DP00085. | ||||||||||||||||||||||||||||||||||||||||||
| ProteinModelPortal | Q04206. | ||||||||||||||||||||||||||||||||||||||||||
| ModBase | Search... | ||||||||||||||||||||||||||||||||||||||||||
Protein-protein interaction databases | |||||||||||||||||||||||||||||||||||||||||||
| DIP | DIP-24238N. | ||||||||||||||||||||||||||||||||||||||||||
| IntAct | Q04206. 72 interactions. | ||||||||||||||||||||||||||||||||||||||||||
| MINT | MINT-106444. | ||||||||||||||||||||||||||||||||||||||||||
| STRING | 9606.ENSP00000384273. | ||||||||||||||||||||||||||||||||||||||||||
PTM databases | |||||||||||||||||||||||||||||||||||||||||||
| PhosphoSite | Q04206. | ||||||||||||||||||||||||||||||||||||||||||
Polymorphism databases | |||||||||||||||||||||||||||||||||||||||||||
| DMDM | 62906901. | ||||||||||||||||||||||||||||||||||||||||||
Proteomic databases | |||||||||||||||||||||||||||||||||||||||||||
| PaxDb | Q04206. | ||||||||||||||||||||||||||||||||||||||||||
| PRIDE | Q04206. | ||||||||||||||||||||||||||||||||||||||||||
Protocols and materials databases | |||||||||||||||||||||||||||||||||||||||||||
| DNASU | 5970. | ||||||||||||||||||||||||||||||||||||||||||
| StructuralBiologyKnowledgebase | Search... | ||||||||||||||||||||||||||||||||||||||||||
Genome annotation databases | |||||||||||||||||||||||||||||||||||||||||||
| Ensembl | ENST00000308639; ENSP00000311508; ENSG00000173039. ENST00000406246; ENSP00000384273; ENSG00000173039. | ||||||||||||||||||||||||||||||||||||||||||
| GeneID | 5970. | ||||||||||||||||||||||||||||||||||||||||||
| KEGG | hsa:5970. | ||||||||||||||||||||||||||||||||||||||||||
| UCSC | uc001off.3. human. uc001ofh.3. human. | ||||||||||||||||||||||||||||||||||||||||||
Organism-specific databases | |||||||||||||||||||||||||||||||||||||||||||
| CTD | 5970. | ||||||||||||||||||||||||||||||||||||||||||
| GeneCards | GC11M065421. | ||||||||||||||||||||||||||||||||||||||||||
| HGNC | HGNC:9955. RELA. | ||||||||||||||||||||||||||||||||||||||||||
| HPA | CAB004264. CAB005030. | ||||||||||||||||||||||||||||||||||||||||||
| MIM | 164014. gene. | ||||||||||||||||||||||||||||||||||||||||||
| neXtProt | NX_Q04206. | ||||||||||||||||||||||||||||||||||||||||||
| PharmGKB | PA296. | ||||||||||||||||||||||||||||||||||||||||||
| GenAtlas | Search... | ||||||||||||||||||||||||||||||||||||||||||
Phylogenomic databases | |||||||||||||||||||||||||||||||||||||||||||
| eggNOG | NOG119056. | ||||||||||||||||||||||||||||||||||||||||||
| HOGENOM | HOG000230474. | ||||||||||||||||||||||||||||||||||||||||||
| HOVERGEN | HBG017916. | ||||||||||||||||||||||||||||||||||||||||||
| InParanoid | Q04206. | ||||||||||||||||||||||||||||||||||||||||||
| KO | K04735. | ||||||||||||||||||||||||||||||||||||||||||
| OMA | EFSPMVF. | ||||||||||||||||||||||||||||||||||||||||||
| OrthoDB | EOG4NVZK2. | ||||||||||||||||||||||||||||||||||||||||||
| PhylomeDB | Q04206. | ||||||||||||||||||||||||||||||||||||||||||
Enzyme and pathway databases | |||||||||||||||||||||||||||||||||||||||||||
| Pathway_Interaction_DB | angiopoietinreceptor_pathway. Angiopoietin receptor Tie2-mediated signaling. nfkappabatypicalpathway. Atypical NF-kappaB pathway. bcr_5pathway. BCR signaling pathway. nfkappabcanonicalpathway. Canonical NF-kappaB pathway. ceramidepathway. Ceramide signaling pathway. fcer1pathway. Fc-epsilon receptor I signaling in mast cells. hivnefpathway. HIV-1 Nef: Negative effector of Fas and TNF-alpha. il1pathway. IL1-mediated signaling events. il12_2pathway. IL12-mediated signaling events. il2_pi3kpathway. IL2 signaling events mediated by PI3K. il23pathway. IL23-mediated signaling events. lysophospholipid_pathway. LPA receptor mediated events. avb3_opn_pathway. Osteopontin-mediated events. hdac_classi_pathway. Signaling events mediated by HDAC Class I. tnfpathway. TNF receptor signaling pathway. | ||||||||||||||||||||||||||||||||||||||||||
| Reactome | REACT_111102. Signal Transduction. REACT_6782. TRAF6 Mediated Induction of proinflammatory cytokines. REACT_6900. Immune System. | ||||||||||||||||||||||||||||||||||||||||||
Gene expression databases | |||||||||||||||||||||||||||||||||||||||||||
| ArrayExpress | Q04206. | ||||||||||||||||||||||||||||||||||||||||||
| Bgee | Q04206. | ||||||||||||||||||||||||||||||||||||||||||
| CleanEx | HS_RELA. | ||||||||||||||||||||||||||||||||||||||||||
| Genevestigator | Q04206. | ||||||||||||||||||||||||||||||||||||||||||
| GermOnline | ENSG00000173039. Homo sapiens. | ||||||||||||||||||||||||||||||||||||||||||
Family and domain databases | |||||||||||||||||||||||||||||||||||||||||||
| Gene3D | 2.60.40.10. 1 hit. 2.60.40.340. 1 hit. | ||||||||||||||||||||||||||||||||||||||||||
| InterPro | IPR013783. Ig-like_fold. IPR014756. Ig_E-set. IPR002909. IPT_TIG_rcpt. IPR000451. NF_Rel_Dor. IPR008967. p53-like_TF_DNA-bd. IPR011539. RHD. [Graphical view] | ||||||||||||||||||||||||||||||||||||||||||
| Pfam | PF00554. RHD. 1 hit. [Graphical view] | ||||||||||||||||||||||||||||||||||||||||||
| PRINTS | PR00057. NFKBTNSCPFCT. | ||||||||||||||||||||||||||||||||||||||||||
| SMART | SM00429. IPT. 1 hit. [Graphical view] | ||||||||||||||||||||||||||||||||||||||||||
| SUPFAM | SSF81296. Ig_E-set. 1 hit. SSF49417. P53_like_DNA_bnd. 1 hit. | ||||||||||||||||||||||||||||||||||||||||||
| PROSITE | PS01204. REL_1. 1 hit. PS50254. REL_2. 1 hit. [Graphical view] | ||||||||||||||||||||||||||||||||||||||||||
| ProtoNet | Search... | ||||||||||||||||||||||||||||||||||||||||||
Other | |||||||||||||||||||||||||||||||||||||||||||
| BindingDB | Q04206. | ||||||||||||||||||||||||||||||||||||||||||
| ChEMBL | CHEMBL5533. | ||||||||||||||||||||||||||||||||||||||||||
| ChiTaRS | RELA. human. | ||||||||||||||||||||||||||||||||||||||||||
| EvolutionaryTrace | Q04206. | ||||||||||||||||||||||||||||||||||||||||||
| GenomeRNAi | 5970. | ||||||||||||||||||||||||||||||||||||||||||
| NextBio | 23241. | ||||||||||||||||||||||||||||||||||||||||||
| SOURCE | Search... | ||||||||||||||||||||||||||||||||||||||||||
Entry information
| Entry name | TF65_HUMAN | ||||||||
| Accession | Primary (citable) accession number: Q04206 Secondary accession number(s): Q6GTV1, Q6SLK1 | ||||||||
| Entry history |
| ||||||||
| Entry status | Reviewed (UniProtKB/Swiss-Prot) | ||||||||
| Annotation program | Chordata Protein Annotation Program | ||||||||
| Disclaimer | Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care. | ||||||||
Relevant documents
| Human chromosome 11 Human chromosome 11: entries, gene names and cross-references to MIM |
| MIM cross-references Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot |
| PDB cross-references Index of Protein Data Bank (PDB) cross-references |
| SIMILARITY comments Index of protein domains and families |

Clusters with
